Sulfato ferroso

Mechanism of Action
Replaces iron, found in hemoglobin, myoglobin, and other enzymes; allows the
transportation of oxygen via hemoglobin

Pharmacodynamics/Kinetics
Onset of action: Hematologic response: Oral: ~3-10 days

Peak effect: Reticulocytosis: 5-10 days; hemoglobin increases within 2-4 weeks

Absorption: Iron is absorbed in the duodenum and upper jejunum; in persons with normal
serum iron stores, 10% of an oral dose is absorbed; this is increased to 20% to 30%
in persons with inadequate iron stores. Food and achlorhydria will decrease
absorption

Protein binding: To transferrin

Excretion: Urine, sweat, sloughing of the intestinal mucosa, and menses

Adverse Reactions
Frequency not defined.

>10%: Gastrointestinal: Constipation, darkening of stools, epigastric pain,

gastrointestinal irritation, nausea, stomach cramps, vomiting

1% to 10%:

Gastrointestinal: Dental discoloration (temporary; liquid preparations), diarrhea,

heartburn

Genitourinary: Urine discoloration

<1%, postmarketing, and/or case reports: Contact dermatitis

Contraindications
Hypersensitivity to iron salts or any component of the formulation; hemochromatosis,
hemolytic anemia

Reference Range
Serum iron:

Males: 75 to 175 mcg/dL (SI: 13.4 to 31.3 micromole/L)

Females: 65 to 165 mcg/dL (SI: 11.6 to 29.5 micromole/L)

Serum ferritin (Ineck 2008):

Males: 15 to 200 ng/dL

Females: 12 to 150 ng/dL

Total iron binding capacity: 230 to 430 mcg/dL

Transferrin: 204 to 360 mg/dL

Percent transferrin saturation: 20% to 50%

Infants 6 months to Children <2 years: 10 to 12.5 mg daily for 3 consecutive months in
a year

Children 2 years to <5 years: 30 mg daily for 3 consecutive months in a year

Children 5 to 12 years: 30 to 60 mg daily for 3 consecutive months in a year

Adolescent menstruating females (non-pregnant females of reproductive potential): 30

to 60 mg daily for 3 consecutive months in a year

Iron deficiency anemia, treatment of iron deficiency: Oral: 3 to 6 mg/kg/day in 3 divided

dose